CN1765374A - 灵芝咀嚼片的制备方法及产品 - Google Patents
灵芝咀嚼片的制备方法及产品 Download PDFInfo
- Publication number
- CN1765374A CN1765374A CN 200510200612 CN200510200612A CN1765374A CN 1765374 A CN1765374 A CN 1765374A CN 200510200612 CN200510200612 CN 200510200612 CN 200510200612 A CN200510200612 A CN 200510200612A CN 1765374 A CN1765374 A CN 1765374A
- Authority
- CN
- China
- Prior art keywords
- ganoderma
- fine powder
- water extract
- precipitation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 62
- 229940068682 chewable tablet Drugs 0.000 title claims abstract description 50
- 239000007910 chewable tablet Substances 0.000 title claims abstract description 50
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 47
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 47
- 229940095710 chewable product Drugs 0.000 title abstract description 3
- 241000222336 Ganoderma Species 0.000 claims abstract description 187
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 129
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 30
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims description 83
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 73
- 238000012869 ethanol precipitation Methods 0.000 claims description 52
- 238000001556 precipitation Methods 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 29
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 239000008187 granular material Substances 0.000 claims description 23
- 238000005406 washing Methods 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
- 239000008101 lactose Substances 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 230000006837 decompression Effects 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 230000001376 precipitating effect Effects 0.000 claims description 11
- 238000004064 recycling Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 abstract description 28
- 239000000470 constituent Substances 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 46
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 230000037396 body weight Effects 0.000 description 38
- 241000699670 Mus sp. Species 0.000 description 34
- 230000000694 effects Effects 0.000 description 27
- 239000000126 substance Substances 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 22
- 239000003826 tablet Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 210000000952 spleen Anatomy 0.000 description 16
- 239000002253 acid Substances 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 230000000242 pagocytic effect Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 235000019658 bitter taste Nutrition 0.000 description 10
- 230000004584 weight gain Effects 0.000 description 10
- 235000019786 weight gain Nutrition 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 241001494479 Pecora Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 210000003024 peritoneal macrophage Anatomy 0.000 description 9
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 230000007306 turnover Effects 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000002262 irrigation Effects 0.000 description 7
- 238000003973 irrigation Methods 0.000 description 7
- 150000003648 triterpenes Chemical class 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010013183 Dislocation of vertebra Diseases 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 206010033888 Paraphilia Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 229950005162 benexate Drugs 0.000 description 6
- 239000012531 culture fluid Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 239000000306 component Substances 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000003228 hemolysin Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 229940046011 buccal tablet Drugs 0.000 description 4
- 239000006189 buccal tablet Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- CJDPJFRMHVXWPT-UHFFFAOYSA-N barium sulfide Chemical compound [S-2].[Ba+2] CJDPJFRMHVXWPT-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 229930182483 coumarin glycoside Natural products 0.000 description 1
- 150000008140 coumarin glycosides Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229930190484 ganoderol Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
水平 | 灵芝醇溶物∶β-环糊精(克分子比) | 搅拌时间(h) | 制备温度(℃) |
123 | 1∶31∶51∶7 | 246 | 406080 |
样品 | 1 | 2 | 3 | 4 |
口感 | 先甜后苦 | 入口即苦 | 入口即苦 | 溶化均甜 |
样口 | 1 | 2 | 3 | 4 |
压片 | 很粘冲 | 有粘冲现象 | 少有粘冲现象 | 无粘冲现象 |
外观 | 表面粗糙 | 表面有麻点 | 表面光滑 | 表面光滑、光亮 |
色泽 | 有暗斑 | 均匀 | 均匀 | 均匀 |
样品 | 第0天 | 第5天 | 第10天 | ||
试验前重(g) | 试验后重(g) | 增重(%) | 试验后重(g) | 增重(%) | |
123456 | 10.167210.103910.201610.009110.011210.0059 | 10.808410.726010.738810.047710.301010.1004 | 6.316.165.274.672.890.94 | 11.044410.963711.010610.552610.469710.1400 | 9.318.517.935.434.581.34 |
剂量组别(mg/kg) | 动物数(只) | 体重及增重(g) | |||
起始体重 | 第14d | 第28d | 体重增重 | ||
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 20.0±1.020.0±0.820.0±0.920.0±0.8 | 23.5±0.523.8±0.823.9±0.823.9±1.0 | 26.8±1.326.4±1.025.8±1.326.3±1.2 | 6.8±1.76.5±1.25.8±1.76.4±1.7 |
剂量组别(mg/kg) | 动物数(只) | 体重及增重(g) | |||
起始体重 | 第14d | 第28d | 体重增重 | ||
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 21.3±0.520.8±0.921.1±0.621.0±1.2 | 32.4±2.532.0±3.132.4±2.732.9±3.0 | 42.3±2.142.7±1.443.7±1.943.0±2.0 | 20.1±1.921.9±1.722.6±1.722.1±1.8 |
剂量组别(mg/kg) | 动物数(只) | 体重及增重(g) | |||
起始体重 | 第14d | 第28d | 体重增重 | ||
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 21.3±0.620.9±1.121.2±0.821.3±0.9 | 32.8±3.032.7±2.733.4±2.733.2±2.1 | 42.2±1.942.8±2.342.2±2.643.8±3.1 | 20.9±2.321.9±2.621.0±2.122.6±3.0 |
剂量组别(mg/kg) | 动物数(只) | 体重及增重(g) | |||
起始体重 | 第14d | 第28d | 体重增重 | ||
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 101010210 | 20.9±0.821.0±0.81.2±0.920.4±1.0 | 32.3±2.732.4±1.632.3±2.032.6±2.0 | 41.8±2.543.0±2.543.1±2.043.4±2.8 | 20.9±2.422.0±2.722.0±2.623.0±3.0 |
剂量组别(mg/kg) | 动物数(只) | 体重及增重(g) | |||
起始体重 | 第14d | 第28d | 体重增重 | ||
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 20.2±1.020.6±1.119.9±1.420.1±0.8 | 32.0±3.532.3±2.832.2±2.732.7±2.7 | 42.6±2.943.1±2.443.6±2.144.0±2.2 | 22.4±2.722.5±2.323.7±2.523.9±2.4 |
剂量组别(mg/kg) | 动物数(只) | 体重及增重(g) | |||
起始体重 | 第14d | 第28d | 体重增重 | ||
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 20.0±1.120.4±1.020.4±0.720.3±1.1 | 32.4±3.332.9±2.632.4±3.033.1±2.1 | 41.7±4.043.6±2.543.7±2.443.8±2.4 | 21.7±3.923.2±2.823.3±2.623.5±2.1 |
剂量组别(mg/kg) | 动物数(只) | 体重及增重(g) | |||
起始体重 | 第14 | 第28d | 体重增重 | ||
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 20.1±0.520.1±1.020.2±1.019.9±1.2 | 24.6±1.324.3±1.125.1±1.325.2±1.0 | 27.5±1.727.4±1.628.1±2.128.2±1.0 | 7.4±2.07.3±1.87.9±2.38.4±1.6 |
剂量组别 | 动物数(只) | 脾脏体重 | 胸腺体重 |
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 2.68±0.242.65±0.312.60±0.332.62±0.15 | 1.57±0.231.70±0.241.85±0.241.64±0.32 |
剂量组别(mg/kg) | 动物数(只) | ConA孔光密度-不加CinA孔光密度差值 |
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 0.010±0.0070.012±0.0060.017±0.0120.022±0.013* |
剂量组别(mg/kg) | 动物数(只) | 耳片重量差值(mg) |
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 30.9±4.127.3±9.537.2±2.743.4±5.7* |
剂量组别(mg/kg) | 动物数(只) | 溶血空斑数(个/100脾细胞) |
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 252±28.2268±27.8296±51.0382±58.1* |
剂量组别(mg/kg) | 动物数(只) | 抗体积数# |
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 1.685±0.240(48.4±1.7)2.139±0.148(137.7±1.4)2.203±0.132*(159.6±1.4)2.300±0.123*(199.5±1.3) |
剂量组别(mg/kg) | 动物数(只) | 吞噬指数 |
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 7.53±1.187.77±0.928.20±1.138.82±1.08* |
剂量组别(mg/kg) | 动物数(只) | 吞噬率 | 吞噬指数 |
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 18.6±4.121.4±4.127.6±6.0*33.6±7.3* | 0.226±0.0520.284±0.0550.334±0.081*0.416±0.101* |
剂量组别(mg/kg) | 动物数(只) | NK细胞活性(%) |
正常对照灵芝片灵芝胶囊灵芝咀嚼片 | 10101010 | 9.1±5.334.3±16.0*40.1±15.5*47.9±15.0* |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005102006126A CN100364554C (zh) | 2005-10-14 | 2005-10-14 | 灵芝咀嚼片的制备方法及产品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005102006126A CN100364554C (zh) | 2005-10-14 | 2005-10-14 | 灵芝咀嚼片的制备方法及产品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1765374A true CN1765374A (zh) | 2006-05-03 |
CN100364554C CN100364554C (zh) | 2008-01-30 |
Family
ID=36741623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005102006126A Expired - Fee Related CN100364554C (zh) | 2005-10-14 | 2005-10-14 | 灵芝咀嚼片的制备方法及产品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100364554C (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101912084A (zh) * | 2010-07-30 | 2010-12-15 | 合肥工业大学 | 一种灵芝脱苦及灵芝饮料制作的方法 |
CN103652919A (zh) * | 2013-12-11 | 2014-03-26 | 罗永祺 | 一种山萸肉灵芝山药咀嚼片及制备方法 |
CN104323252A (zh) * | 2014-11-04 | 2015-02-04 | 苏州硒泰克生物科技有限公司 | 一种高硒灵芝菌丝体咀嚼片及其制备方法 |
CN106265811A (zh) * | 2016-08-31 | 2017-01-04 | 中国热带农业科学院热带作物品种资源研究所 | 一种含有艾纳香提取物的口腔咀嚼片 |
CN108477598A (zh) * | 2018-03-16 | 2018-09-04 | 南京财经大学 | 基于食用菌副产物的多糖灵芝孢子粉复配片剂及制备工艺 |
CN110447889A (zh) * | 2019-08-23 | 2019-11-15 | 广州白云山汉方现代药业有限公司 | 一种灵芝提取物的制备方法 |
CN111417382A (zh) * | 2017-09-28 | 2020-07-14 | 株式会社爱茉莉太平洋 | 利用环保提取技术的灵芝提取物的制造方法、由此制造的灵芝提取物以及含有其的抗老化化妆品组合物 |
CN114223896A (zh) * | 2021-11-18 | 2022-03-25 | 西北农林科技大学 | 一种红枣三萜酸咀嚼片及其制备方法 |
CN116531415A (zh) * | 2023-06-14 | 2023-08-04 | 贵州省生物技术研究所(贵州省生物技术重点实验室、贵州省马铃薯研究所、贵州省食品加工研究所) | 一种灵芝水煎液祛苦的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1133737A (zh) * | 1995-04-17 | 1996-10-23 | 浙江省微生物研究所 | 灵芝含片及制备工艺 |
-
2005
- 2005-10-14 CN CNB2005102006126A patent/CN100364554C/zh not_active Expired - Fee Related
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101912084A (zh) * | 2010-07-30 | 2010-12-15 | 合肥工业大学 | 一种灵芝脱苦及灵芝饮料制作的方法 |
CN103652919A (zh) * | 2013-12-11 | 2014-03-26 | 罗永祺 | 一种山萸肉灵芝山药咀嚼片及制备方法 |
CN103652919B (zh) * | 2013-12-11 | 2015-07-22 | 罗永祺 | 一种山萸肉灵芝山药咀嚼片及制备方法 |
CN104323252A (zh) * | 2014-11-04 | 2015-02-04 | 苏州硒泰克生物科技有限公司 | 一种高硒灵芝菌丝体咀嚼片及其制备方法 |
CN106265811A (zh) * | 2016-08-31 | 2017-01-04 | 中国热带农业科学院热带作物品种资源研究所 | 一种含有艾纳香提取物的口腔咀嚼片 |
CN111417382A (zh) * | 2017-09-28 | 2020-07-14 | 株式会社爱茉莉太平洋 | 利用环保提取技术的灵芝提取物的制造方法、由此制造的灵芝提取物以及含有其的抗老化化妆品组合物 |
US11433019B2 (en) * | 2017-09-28 | 2022-09-06 | Amorepacific Corporation | Ganoderma lucidum extract-preparing method using eco-friendly extraction technique, Ganoderma lucidum extract prepared thereby, and anti-aging cosmetic composition comprising same extract |
CN111417382B (zh) * | 2017-09-28 | 2023-06-16 | 株式会社爱茉莉太平洋 | 利用环保提取技术的灵芝提取物的制造方法、由此制造的灵芝提取物以及含有其的抗老化化妆品组合物 |
CN108477598A (zh) * | 2018-03-16 | 2018-09-04 | 南京财经大学 | 基于食用菌副产物的多糖灵芝孢子粉复配片剂及制备工艺 |
CN110447889A (zh) * | 2019-08-23 | 2019-11-15 | 广州白云山汉方现代药业有限公司 | 一种灵芝提取物的制备方法 |
CN114223896A (zh) * | 2021-11-18 | 2022-03-25 | 西北农林科技大学 | 一种红枣三萜酸咀嚼片及其制备方法 |
CN116531415A (zh) * | 2023-06-14 | 2023-08-04 | 贵州省生物技术研究所(贵州省生物技术重点实验室、贵州省马铃薯研究所、贵州省食品加工研究所) | 一种灵芝水煎液祛苦的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100364554C (zh) | 2008-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1765374A (zh) | 灵芝咀嚼片的制备方法及产品 | |
CN1876139A (zh) | 治疗小儿厌食症的药物制剂及其制备方法和质量控制方法 | |
CN1857642A (zh) | 一种解郁安神制剂的质量控制方法 | |
CA2871478C (en) | Pleuropterus multiflorus extract and dipsacus asperoides extract for stimulating the secretion of insulin-like growth factor and promoting bone structure growth, and method for preparing same | |
CN1709341A (zh) | 一种益气健脾的药物组合物及其制备方法和用途 | |
CN1814170A (zh) | 一种治疗心血管疾病的药物滴丸及其制备方法 | |
CN100344321C (zh) | 一种药物组合物及其制备方法、质量控制方法 | |
CN100346820C (zh) | 金地蓝解毒药物组合物、制剂及制备方法 | |
CN1931255A (zh) | 治疗血小板减少、贫血的药物及制备方法和质量控制方法 | |
CN1194742C (zh) | 一种具有延缓衰老和改善睡眠功能的中药组合物及其制备方法 | |
CN1310638C (zh) | 一种儿童健脾开胃泡腾片及其制备方法 | |
CN1857588A (zh) | 一种仙灵骨葆制剂的质量控制方法 | |
CN1316960C (zh) | 复方蛤青滴丸及其制备方法 | |
CN1048879C (zh) | 一种治疗原发性肾小球疾病及乳糜尿的药物及其制备方法 | |
CN1615959A (zh) | 治疗皮肤疾病的中药胶囊制剂 | |
CN1186351C (zh) | 黄花倒水莲总皂苷及其药物组合物与制备方法 | |
CN1244350C (zh) | 一种具有健脾消积作用的中药组合物及其制备方法 | |
CN1301099C (zh) | 地龙滴丸及其制备方法 | |
CN1220510C (zh) | 一种益气补血养心安神的中成药及其制备方法质量控制方法 | |
CN109294984A (zh) | 一种体内高效扩增nk细胞的香菇多糖胶囊及其制备方法 | |
CN1559527A (zh) | 一种复方百部止咳药物及其制备方法 | |
CN1432374A (zh) | 用于治疗肾虚的药物及其制备方法 | |
CN1583133A (zh) | 一种治疗骨科疾病的泡腾片及其制备方法 | |
CN1490045A (zh) | 剑麻提取物及其制备方法和用途 | |
CN1232274C (zh) | 一种防治骨质疏松的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ANKANG PHARMACEUTICAL CO., LTD., GUIZHOU Free format text: FORMER OWNER: CHEN SHA Effective date: 20101216 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Fan Meijun Inventor before: Chen Sha |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 550004 GUIZHOU ANKANG PHARMACEUTICAL CO., LTD., 7/F, UNIT 3, NO. 1, BEIXIN LANE, GUIYANG CITY, GUIZHOU PROVINCE TO: 551400 YIYAO INDUSTRIAL PARK, QINGZHEN TOWN, GUIYANG CITY, GUIZHOU PROVINCE Free format text: CORRECT: INVENTOR; FROM: CHEN SHA TO: FAN MEIJUN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101216 Address after: 551400 Guizhou province Guiyang Qingzhen Pharmaceutical Industrial Park Patentee after: Ankang Pharmaceutical Co., Ltd., Guizhou Address before: 550004 Guizhou Ankang Pharmaceutical Co., Ltd., building 7, No. 3, Lane 1, North Lane, Guizhou, Guiyang Patentee before: Chen Sha |
|
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Duan Gang Inventor before: Fan Meijun |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FAN MEIJUN TO: DUAN GANG |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080130 Termination date: 20121014 |